<p><em><strong>一月会议将重点介绍 Zomedica 不断扩展的数字能力和长期创新战略</strong></em></p>
<p>Zomedica Corp. (OTCQB:ZOMDF)（&#34;Zomedica&#34;或&#34;公司&#34;）是一家为马匹和伴侣动物提供创新诊断和治疗设备的动物健康公司，今天宣布其&#34;每月第四个星期五四点&#34;投资者网络研讨会系列的下一期，定于 <strong>2026 年 1 月 23 日星期五东部时间下午 4:00</strong> 举行。</p>
<p>一月的主题为 <strong>&#34;数字优势：通过创新推动可扩展增长&#34;</strong>，将为投资者提供深入了解 Zomedica 如何构建数字体验和部署数字技术以创造产品创新，从而推动可持续收入扩展、运营杠杆和长期股东价值的机会。讨论将重点介绍公司的数字生态系统、技术驱动的产品管道以及旨在增强 Zomedica 在兽医诊断和治疗领域竞争地位的战略举措。</p>
<p>&#34;Zomedica 的数字战略并不是孤立的技术举措——而是构建连接的智能平台，以推动更好的临床结果，加速产品采用，并创造可扩展、可重复的增长，&#34;Zomedica 创新技术副总裁 <strong>Evan St. Peter</strong> 表示。&#34;随着我们继续在诊断、治疗和数据驱动解决方案方面进行创新投资，我们正在为客户和股东创造长期价值奠定基础。&#34;</p>
<p>投资者和相关利益相关者可以在此注册： https://sholink.to/January2026</p>
<p><strong>网络研讨会详情</strong></p>
<p><strong>标题：</strong> <em>每月第四个星期五四点 - 数字优势：通过创新推动可扩展增长</em></p>
<p>** 日期/时间：**2026 年 1 月 23 日星期五，东部时间下午 4:00</p>
<p><strong>注册：</strong> https://sholink.to/January2026</p>
<p><strong>形式：</strong> 准备好的发言后进行问答环节</p>
<p><strong>关于 Zomedica</strong></p>
<p>Zomedica 是一家领先的马匹和伴侣动物健康公司，致力于通过为兽医提供创新的治疗和诊断解决方案来改善动物健康。我们的金标准 PulseVet®冲击波系统加速了肌肉骨骼疾病的愈合，改变了兽医治疗。我们的产品系列还包括 Assisi®治疗设备系列、TRUFORMA®诊断平台、TRUVIEW®数字细胞学系统、VetGuardian®零接触监测系统和 VETIGEL®止血凝胶，这是一种革命性的止血剂，能够迅速止血，所有这些都旨在赋能兽医提供顶级护理。在美国，它们的总可寻址市场超过 20 亿美元。Zomedica 总部位于密歇根州，雇佣约 150 名员工，并在乔治亚州和明尼苏达州的世界级设施中制造和分销其产品。Zomedica 在 2024 年实现了 8% 的收入增长，达到 2700 万美元，并在 2025 年 9 月 30 日时保持约 5440 万美元的流动资金，资产负债表强劲。Zomedica 正在推进其产品供应，利用战略收购，并在国际上扩展，以提升宠物护理质量，增加宠物家长的满意度，并改善兽医实践的工作流程、现金流和盈利能力。有关更多信息，请访问 www.zomedica.com。</p>
<p><strong>关注 Zomedica</strong></p>
<ul>
<li>邮件提醒： http://investors.zomedica.com</li>
<li>LinkedIn: https://www.linkedin.com/company/zomedica</li>
<li>Facebook: https://m.facebook.com/zomedica</li>
<li>X（前 Twitter）： https://twitter.com/zomedica</li>
<li>Instagram: https://www.instagram.com/zomedica_inc</li>
</ul>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>除历史事实的陈述外，本新闻稿包含某些&#34;前瞻性信息&#34;或&#34;前瞻性声明&#34;（统称&#34;前瞻性信息&#34;），符合适用证券法的定义。前瞻性信息通常以&#34;计划&#34;、&#34;期望&#34;、&#34;预测&#34;、&#34;打算&#34;、&#34;相信&#34;、&#34;预期&#34;、&#34;估计&#34;及其他类似词汇或某些事件或条件&#34;可能&#34;或&#34;将&#34;发生的声明来表述，并包括与我们对未来结果的预期相关的声明。尽管我们相信前瞻性信息中反映的预期是合理的，但不能保证这些预期会被证明是正确的。我们无法保证未来的结果、表现或成就。因此，不能保证实际结果与前瞻性信息中列出的结果在整体或部分上相同。</p>
<p>前瞻性信息基于管理层在声明发布时的意见和估计，包括对经济增长、公司产品需求、公司生产和销售产品能力、预算资本和运营支出的充足性、战略合作伙伴在商业协议下履行义务的满意度以及我们实现商业计划和成本控制努力的能力的假设。</p>
<p>我们的前瞻性信息受到多种风险和不确定性以及其他因素的影响，这些因素可能导致实际事件或结果与前瞻性信息中预期的结果存在重大差异。一些可能导致结果与前瞻性信息中表达的内容存在重大差异的风险和其他因素包括但不限于：临床研究的结果、普遍接受的会计原则的应用，这些原则高度复杂，涉及许多主观假设、估计和判断；我们战略和商业计划是否能带来预期收益的不确定性；开发工作及验证和确认研究的时间和结果的不确定性；商业化努力的时间和结果的不确定性，包括国际努力，以及商业化努力的成本，包括开发内部销售团队和管理我们增长的成本；我们能否实现收购所带来的预期增长机会的不确定性；我们能否根据客户需求供应产品的不确定性；与关税变化相关的供应链风险；任何所需监管批准的可能性和时间的不确定性，以及资本的可用性和成本；识别、开发和实现新产品和技术商业成功的能力；在采用我们的资本设备后，兽医对我们产品的接受度和对耗材的购买；来自相关产品的竞争；维持和提高产品和服务质量所需支出的水平；技术变化和法律法规的变化；我们确保和维持战略关系的能力；我们的战略合作伙伴在商业协议下履行其义务的表现，包括产品制造义务；与许可证和许可相关的风险、知识产权侵权风险、与任何所需临床试验和监管批准相关的风险、与我们产品的安全性和有效性、产品使用、知识产权保护以及在我们向 SEC 提交的文件和在 www.sedarplus.com 上的资料中披露的其他风险因素相关的风险。读者应注意，这份风险因素清单不应被解释为详尽无遗。</p>
<p>本新闻稿中包含的前瞻性信息明确受到本警示声明的限制。除非适用的证券立法另有要求，否则我们不承担更新任何前瞻性信息以使其与实际结果或我们的预期变化相符的义务。读者应谨慎对待前瞻性信息，避免过度依赖。</p>
<p><strong>投资者关系联系人：</strong></p>
<p>Zomedica 投资者关系</p>
<p><strong>Investors@zomedica.com</strong></p>
<p>1-734-369-2555</p>
<p><strong>来源：</strong> Zomedica Corp.</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyNjkzNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyNjkzNQ"/></p>

ZOMDF

<p>Zomedica Corp.（OTCQB:ZOMDF）将于 2026 年 1 月 23 日举办其 “第四个星期五四点钟” 投资者网络研讨会，重点讨论数字创新和技术驱动的增长。此次会议的主题为 “数字优势：通过创新推动可扩展增长”，将展示 Zomedica 的数字能力和长期创新战略，旨在提升兽医诊断和治疗。公司报告称，2024 年收入增长 8%，达到 2700 万美元，并在 2025 年 9 月 30 日保持约 5440 万美元的强劲流动性。感兴趣的利益相关者可以注册参加该网络研讨会</p>

<p><em><strong>January session to highlight Zomedica's expanding digital capabilities and long-term innovation strategy</strong></em></p>
<div class="lb-trans"><p><em><strong>一月会议将重点介绍 Zomedica 不断扩展的数字能力和长期创新战略</strong></em></p>
</div><p>Zomedica Corp. (OTCQB:ZOMDF) (&#34;Zomedica&#34; or the &#34;Company&#34;), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, today announced the next installment of its &#34;Fourth Friday at Four&#34; investor webinar series, scheduled for <strong>Friday, January 23, 2026 at 4:00 p.m. Eastern Time</strong>.</p>
<div class="lb-trans"><p>Zomedica Corp. (OTCQB:ZOMDF)（&#34;Zomedica&#34;或&#34;公司&#34;）是一家为马匹和伴侣动物提供创新诊断和治疗设备的动物健康公司，今天宣布其&#34;每月第四个星期五四点&#34;投资者网络研讨会系列的下一期，定于 <strong>2026 年 1 月 23 日星期五东部时间下午 4:00</strong> 举行。</p>
</div><p>The January program, titled <strong>&#34;Digital Advantage: Powering Scalable Growth Through Innovation,&#34;</strong> will provide investors with an in-depth look at how Zomedica is building digital experiences and deploying digital technology to create product innovation to drive sustainable revenue expansion, operating leverage, and long-term shareholder value. The discussion will highlight the Company's evolving digital ecosystem, technology-enabled product pipeline, and strategic initiatives designed to strengthen Zomedica's competitive position across veterinary diagnostics and therapeutics.</p>
<div class="lb-trans"><p>一月的主题为 <strong>&#34;数字优势：通过创新推动可扩展增长&#34;</strong>，将为投资者提供深入了解 Zomedica 如何构建数字体验和部署数字技术以创造产品创新，从而推动可持续收入扩展、运营杠杆和长期股东价值的机会。讨论将重点介绍公司的数字生态系统、技术驱动的产品管道以及旨在增强 Zomedica 在兽医诊断和治疗领域竞争地位的战略举措。</p>
</div><p>&#34;Zomedica's digital strategy is not about isolated technology initiatives - it is about building connected, intelligent platforms that drive better clinical outcomes, accelerate product adoption, and create scalable, repeatable growth,&#34; said <strong>Evan St. Peter, Vice President of Innovation Technology at Zomedica</strong>. &#34;As we continue to invest in innovation across diagnostics, therapeutics, and data-driven solutions, we are creating a foundation for long-term value creation for both customers and shareholders.&#34;</p>
<div class="lb-trans"><p>&#34;Zomedica 的数字战略并不是孤立的技术举措——而是构建连接的智能平台，以推动更好的临床结果，加速产品采用，并创造可扩展、可重复的增长，&#34;Zomedica 创新技术副总裁 <strong>Evan St. Peter</strong> 表示。&#34;随着我们继续在诊断、治疗和数据驱动解决方案方面进行创新投资，我们正在为客户和股东创造长期价值奠定基础。&#34;</p>
</div><p>Investors and interested stakeholders can register here: https://sholink.to/January2026</p>
<div class="lb-trans"><p>投资者和相关利益相关者可以在此注册： https://sholink.to/January2026</p>
</div><p><strong>Webinar Details</strong></p>
<div class="lb-trans"><p><strong>网络研讨会详情</strong></p>
</div><p><strong>Title:</strong> <em>Fourth Friday at Four - Digital Advantage: Powering Scalable Growth Through Innovation</em></p>
<div class="lb-trans"><p><strong>标题：</strong> <em>每月第四个星期五四点 - 数字优势：通过创新推动可扩展增长</em></p>
</div><p><strong>Date/Time:</strong> Friday, January 23, 2026, at 4:00 p.m. Eastern Time</p>
<div class="lb-trans"><p>** 日期/时间：**2026 年 1 月 23 日星期五，东部时间下午 4:00</p>
</div><p><strong>Registration:</strong> https://sholink.to/January2026</p>
<div class="lb-trans"><p><strong>注册：</strong> https://sholink.to/January2026</p>
</div><p><strong>Format:</strong> Prepared remarks followed by Question &amp; Answer session</p>
<div class="lb-trans"><p><strong>形式：</strong> 准备好的发言后进行问答环节</p>
</div><p><strong>About Zomedica</strong></p>
<div class="lb-trans"><p><strong>关于 Zomedica</strong></p>
</div><p>Zomedica is a leading equine and companion animal health company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® line of therapeutic devices, the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, the VetGuardian® Zero Touch™ monitoring system, and VETIGEL® hemostatic gel, a revolutionary hemostatic agent that rapidly stops bleeding, all designed to empower veterinarians to deliver top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $54.4 million in liquidity as of September 30, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as it works to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.</p>
<div class="lb-trans"><p>Zomedica 是一家领先的马匹和伴侣动物健康公司，致力于通过为兽医提供创新的治疗和诊断解决方案来改善动物健康。我们的金标准 PulseVet®冲击波系统加速了肌肉骨骼疾病的愈合，改变了兽医治疗。我们的产品系列还包括 Assisi®治疗设备系列、TRUFORMA®诊断平台、TRUVIEW®数字细胞学系统、VetGuardian®零接触监测系统和 VETIGEL®止血凝胶，这是一种革命性的止血剂，能够迅速止血，所有这些都旨在赋能兽医提供顶级护理。在美国，它们的总可寻址市场超过 20 亿美元。Zomedica 总部位于密歇根州，雇佣约 150 名员工，并在乔治亚州和明尼苏达州的世界级设施中制造和分销其产品。Zomedica 在 2024 年实现了 8% 的收入增长，达到 2700 万美元，并在 2025 年 9 月 30 日时保持约 5440 万美元的流动资金，资产负债表强劲。Zomedica 正在推进其产品供应，利用战略收购，并在国际上扩展，以提升宠物护理质量，增加宠物家长的满意度，并改善兽医实践的工作流程、现金流和盈利能力。有关更多信息，请访问 www.zomedica.com。</p>
</div><p><strong>Follow Zomedica</strong></p>
<div class="lb-trans"><p><strong>关注 Zomedica</strong></p>
</div><ul>
<li>Email Alerts: http://investors.zomedica.com</li>
<li>LinkedIn: https://www.linkedin.com/company/zomedica</li>
<li>Facebook: https://m.facebook.com/zomedica</li>
<li>X (formerly Twitter): https://twitter.com/zomedica</li>
<li>Instagram: https://www.instagram.com/zomedica_inc</li>
</ul>
<div class="lb-trans"><ul>
<li>邮件提醒： http://investors.zomedica.com</li>
<li>LinkedIn: https://www.linkedin.com/company/zomedica</li>
<li>Facebook: https://m.facebook.com/zomedica</li>
<li>X（前 Twitter）： https://twitter.com/zomedica</li>
<li>Instagram: https://www.instagram.com/zomedica_inc</li>
</ul>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>Except for statements of historical fact, this news release contains certain &#34;forward-looking information&#34; or &#34;forward-looking statements&#34; (collectively, &#34;forward-looking information&#34;) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as &#34;plan&#34;, &#34;expect&#34;, &#34;project&#34;, &#34;intend&#34;, &#34;believe&#34;, &#34;anticipate&#34;, &#34;estimate&#34; and other similar words, or statements that certain events or conditions &#34;may&#34; or &#34;will&#34; occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.</p>
<div class="lb-trans"><p>除历史事实的陈述外，本新闻稿包含某些&#34;前瞻性信息&#34;或&#34;前瞻性声明&#34;（统称&#34;前瞻性信息&#34;），符合适用证券法的定义。前瞻性信息通常以&#34;计划&#34;、&#34;期望&#34;、&#34;预测&#34;、&#34;打算&#34;、&#34;相信&#34;、&#34;预期&#34;、&#34;估计&#34;及其他类似词汇或某些事件或条件&#34;可能&#34;或&#34;将&#34;发生的声明来表述，并包括与我们对未来结果的预期相关的声明。尽管我们相信前瞻性信息中反映的预期是合理的，但不能保证这些预期会被证明是正确的。我们无法保证未来的结果、表现或成就。因此，不能保证实际结果与前瞻性信息中列出的结果在整体或部分上相同。</p>
</div><p>Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.</p>
<div class="lb-trans"><p>前瞻性信息基于管理层在声明发布时的意见和估计，包括对经济增长、公司产品需求、公司生产和销售产品能力、预算资本和运营支出的充足性、战略合作伙伴在商业协议下履行义务的满意度以及我们实现商业计划和成本控制努力的能力的假设。</p>
</div><p>Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.</p>
<div class="lb-trans"><p>我们的前瞻性信息受到多种风险和不确定性以及其他因素的影响，这些因素可能导致实际事件或结果与前瞻性信息中预期的结果存在重大差异。一些可能导致结果与前瞻性信息中表达的内容存在重大差异的风险和其他因素包括但不限于：临床研究的结果、普遍接受的会计原则的应用，这些原则高度复杂，涉及许多主观假设、估计和判断；我们战略和商业计划是否能带来预期收益的不确定性；开发工作及验证和确认研究的时间和结果的不确定性；商业化努力的时间和结果的不确定性，包括国际努力，以及商业化努力的成本，包括开发内部销售团队和管理我们增长的成本；我们能否实现收购所带来的预期增长机会的不确定性；我们能否根据客户需求供应产品的不确定性；与关税变化相关的供应链风险；任何所需监管批准的可能性和时间的不确定性，以及资本的可用性和成本；识别、开发和实现新产品和技术商业成功的能力；在采用我们的资本设备后，兽医对我们产品的接受度和对耗材的购买；来自相关产品的竞争；维持和提高产品和服务质量所需支出的水平；技术变化和法律法规的变化；我们确保和维持战略关系的能力；我们的战略合作伙伴在商业协议下履行其义务的表现，包括产品制造义务；与许可证和许可相关的风险、知识产权侵权风险、与任何所需临床试验和监管批准相关的风险、与我们产品的安全性和有效性、产品使用、知识产权保护以及在我们向 SEC 提交的文件和在 www.sedarplus.com 上的资料中披露的其他风险因素相关的风险。读者应注意，这份风险因素清单不应被解释为详尽无遗。</p>
</div><p>The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.</p>
<div class="lb-trans"><p>本新闻稿中包含的前瞻性信息明确受到本警示声明的限制。除非适用的证券立法另有要求，否则我们不承担更新任何前瞻性信息以使其与实际结果或我们的预期变化相符的义务。读者应谨慎对待前瞻性信息，避免过度依赖。</p>
</div><p><strong>Investor Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者关系联系人：</strong></p>
</div><p>Zomedica Investor Relations</p>
<div class="lb-trans"><p>Zomedica 投资者关系</p>
</div><p><strong>Investors@zomedica.com</strong></p>
<div class="lb-trans"><p><strong>Investors@zomedica.com</strong></p>
</div><p>1-734-369-2555</p>
<div class="lb-trans"><p>1-734-369-2555</p>
</div><p><strong>SOURCE:</strong> Zomedica Corp.</p>
<div class="lb-trans"><p><strong>来源：</strong> Zomedica Corp.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyNjkzNQ" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1126935"/></p>

Zomedica 宣布将于 1 月 23 日举办 “第四个星期五下午四点” 网络研讨会，重点讨论数字创新和技术驱动的增长 | ZOMDF 股票新闻